The CAMDEX (Cambridge Mental Disorders of the Elderly Examination) is a widely used instrument for the diagnosis of dementia. It contains a cognitive section (CAMCOG) which consists of 60 items grouped into eight a priori subscales (orientation, language, memory, praxis, attention, abstract thinking
The single eeg in alzheimer's disease: What value for prognosis?
β Scribed by L. Bach; J. McCulloch; R. Hunter
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 331 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0885-6230
No coin nor oath required. For personal study only.
β¦ Synopsis
The article reports an investigation into whether abnormal EEG patterns are predictive of faster rate of decline in patients with Alzheimer's disease. Data for 24 patients with probable Alzheimer's disease (NINCDS-ADRDA criteria) were analysed. Patients were divided into two groups, those with normal EEG pattern ( N = 9) and those with abnormal EEG pattern ( N = 15). There was no difference between the initial MMSE and CAMCOG scores for either group. There was also no difference in terms of rate of decline, as measured by MMSE and CAMCOG scores, between patients with normal and abnormal EEG records. We therefore conclude that the single EEG is of limited value in predicting rate of cognitive decline in Alzheimer patients.
π SIMILAR VOLUMES
## Abstract ## Objective To estimate the value of informal care in Alzheimer's disease using contingent valuation. ## Methods A questionnaire was administered to 517 primary carers in four countries (UK, Spain, Sweden, and US). Dichotomous choice and bidding game methods were used to elicit thei
## Aims To ensure that all Alzheimer centres across Europe are capable of using a similar method of data collection. Information about the patient assessment tools used by each participating centre was obtained and normal clinical practice in each EADC centre was documented by collecting data from
## Abstract Pharmaceutical approaches to slow the progression of Alzheimer's disease (AD) have focused primarily on reducing production or increasing clearance of amyloid Ξ² peptide (AΞ²). Recent clinical trial results question the efficacy of targeting AΞ² for treatment of mild to moderate AD, highli